| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | CMP-SYNGAP-01 SYNGAP1-related disorders | Phase 1/2 | — | RNA-Based Therapies | Nervous System | ||
Phase 1/2 data readout example | CMP-SYNGAP-01 SYNGAP1-related disorders | Phase 1/2 | — | RNA-Based Therapies | Nervous System | ||
Phase 1/2 data readout example | CMP-SYNGAP-01 SYNGAP1-related disorders | Phase 1/2 | — | RNA-Based Therapies | Nervous System |
Recent Updates
Recently added Catalysts
CAMP4 Therapeutics Corporation$4.05
+0.13 (+3.19%)
D 25Pipeline Score Richly Valued Biotech · Clinical
Market Cap
234.19 M
EPS
-2.27
P/E Ratio
-
Value Trade
198.53 K
SEC Financials
Q1 2026Dilution Risk
Revenue
1.29 M
R&D Expenses
10.16 M
Operating CF
-10.98 M
Total Assets
105.46 M
Total Liabilities
74.56 M
Equity
30.90 M
D/E Ratio
12,345
3.92 %
Week
-1.96 %
1 Month
6.77 %
3 Month
27.04 %
6 Month
-59.59 %
5 Year
-59.59 %
All Time
Cash Data
Cash Position
99.21 M
Monthly Burn
3.66 M
Runway
25.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
90.02 K
52 Week Range
1.31 - 7.75
% held by Insiders
48.93 %
% held by Institutions
55.78 %
Enterprise Value
136.37 M
Total Shares
51.96 M
Short %
1.5 %
Float Shares
28.84 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D25
Pipeline Score $18M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 26%
Micro Cap (rank 671 of 905)
Percentile RankCAMP4 Therapeutics Corporation faces pipeline headwinds (25/100), with $70M risk-adjusted pipeline value, led by CMP-CPS-001 in Healthy Volunteers (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CMP-CPS-001 Small molecule | Healthy Volunteers | Phase 1 | NCT06247670 | 7% | $70M | ACTIVE NOT_RECRUITING | 120 | SLOW | C (55) | Dec 1, 2027 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CMP-SYNGAP-01 | SYNGAP1-related disorders | Phase 1 | 2025-08-15 | |||
CMP-SYNGAP-01 | SYNGAP1-related disorders | Phase 1 | 2025-08-15 | |||
CMP-SYNGAP-01 | SYNGAP1-related disorders | Phase 1 | 2025-08-15 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CAMP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CAMP4 Therapeutics Corporation (CAMP) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAMP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
CAMP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
CAMP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CAMPCAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics announced the granting of non-qualified stock options to three new employees as an inducement for their employment. The options, totaling 39,000 shares, have a ten-year term and will vest over four years. This move is part of the company's strategy to enhance its workforce as it develops RNA-targeting therapeutics for genetic diseases.
Read more →CAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 21, 2026
CAMP4 Therapeutics has announced a non-qualified stock option grant to a new employee as an inducement for joining the company. The grant, which includes 5,000 shares, has a ten-year term and an exercise price equal to the stock's closing price on the grant date. The shares will vest over four years, contingent on the employee's continued service.
Read more →CAMPCAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
CAMP4 Therapeutics has presented new preclinical data indicating that CMP-002, its lead investigational therapeutic candidate, significantly enhances seizure threshold and reduces the severity of seizures in a mouse model of SYNGAP1-related disorder. The findings extend earlier evidence of the therapeutic potential of CMP-002, which aims to restore SYNGAP1 protein levels. The company plans to advance CMP-002 into a Phase 1/2 clinical trial in the second half of 2026, marking a critical step in developing treatments for this rare genetic disorder. This development is of significant interest to the biomedical community and could lead to new treatment options for affected individuals.
Read more →CAMPDocument CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder CMP-002 administration resulted in a statistically signific
CAMP4 Therapeutics announced new preclinical data for CMP-002, showing significant improvements in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. This data extends previous findings on the neurodevelopmental benefits of CMP-002, suggesting its potential as a disease-modifying treatment for SYNGAP1-related disorder. The company is set to initiate a Phase 1/2 clinical trial for CMP-002 in the second half of 2026, aiming to address various neurological symptoms associated with the disorder.
Read more →CAMPCAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
CAMP4 Therapeutics has reported its financial results for the first quarter of 2026, highlighting significant progress in its development of CMP-002 for SYNGAP1-related disorders. The company submitted its first regulatory filing in Australia and plans to initiate a global Phase 1/2 clinical trial in the second half of 2026. Additionally, CAMP4 received Orphan Designation from the European Medicines Agency and entered into a collaboration with CURE SYNGAP1 to support ongoing research. Despite a notable increase in net losses, the company's financial stability is supported by $99 million in cash, sufficient to fund operations into 2028.
Read more →CAMPCAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
CAMP4 Therapeutics has submitted a preprint detailing its innovative regRNA Capture-seq methodology, which has led to the identification of a vast catalog of regulatory RNAs. This research aims to enhance gene expression through antisense oligonucleotides, with potential applications in treating genetic diseases. The company plans to advance its lead product candidate, CMP-002, into clinical trials in late 2026.
Read more →CAMPCAMP4 Appoints Michael MacLean to its Board of Directors
CAMP4 Therapeutics has appointed Michael MacLean to its Board of Directors. MacLean brings over 35 years of experience in financial leadership within the biotechnology sector. His expertise is expected to support the advancement of CAMP4's CMP-002 therapy for SYNGAP1-related disorders, which currently lacks approved treatment options.
Read more →CAMPCAMP4 to Participate in Upcoming Investor Conferences - March 6, 2026
CAMP4 Therapeutics Corporation has announced its participation in upcoming investor conferences. The company focuses on developing RNA-targeting therapeutics aimed at treating a variety of genetic diseases by upregulating gene expression. Live webcasts of the presentations will be available on their investor relations page, with replays archived for 30 days.
Read more →CAMPCAMP4 to Participate in Upcoming Investor Conferences
CAMP4 Therapeutics Corporation announced its participation in several upcoming investor conferences, showcasing its commitment to stakeholder engagement. The company will present at the Leerink Partners Global Healthcare Conference, the Stifel CNS Forum, and the Needham & Company Healthcare Conference throughout March and April 2026. These events will provide opportunities for CAMP4 to discuss its pipeline of RNA-targeting therapeutics designed to treat various genetic diseases. Live webcasts of the presentations will be available on CAMP4's investor relations page.
Read more →CAMPCAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics Corporation reported its financial results for the year ending December 31, 2025, highlighting significant advances in its SYNGAP1 program. The company has initiated GLP toxicology studies for CMP-002 and anticipates starting a Phase 1/2 trial as early as the second half of 2026. They entered a strategic partnership with GSK, receiving an upfront payment of $17.5 million and the potential for up to $440 million in milestones. Despite a higher net loss reported for the year, CAMP4's strong cash position supports its developmental goals through 2028.
Read more →CAMPDocument CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1 2 clinical trial in SYNGAP1 patients expected as early as 2H
CAMP4 Therapeutics Corporation has reported its financial results for the year ending December 31, 2025, announcing significant developments in its SYNGAP1 program and a collaboration with GSK. Notably, the company is set to initiate a Phase 1/2 clinical trial for its product CMP-002 in SYNGAP1 patients, with ongoing GLP toxicology studies. Despite achieving a substantial cash runway into 2028, CAMP4 experienced a notable increase in its net loss, prompting the decision to halt further investment in CMP-001. Overall, the company remains focused on advancing its RNA-targeting therapeutic candidates.
Read more →CAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics announced an inducement grant consisting of 8,000 stock options for a new employee, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price set at $3.85 per share, matching the stock's closing price on the grant date. The vesting period is structured over four years, with a quarter vesting after the first year and the remainder vesting monthly. This move highlights CAMP4's commitment to building a strong team to support its pipeline of RNA-targeting therapeutics aimed at treating genetic diseases.
Read more →CAMPCAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
CAMP4 Therapeutics announced an Inducement Grant on January 15, 2026, to a new employee, allowing the purchase of 8,000 shares at $5.78 each. This grant, compliant with Nasdaq Listing Rule 5635(c)(4), will vest over four years. CAMP4 focuses on developing RNA-targeting therapeutics for genetic diseases.
Read more →CAMPjanuary2026co
january2026co
Read more →CAMPCAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMP4 Therapeutics Corporation will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PST. The presentation will feature insights from Josh Mandel-Brehm, the President & CEO, concerning CAMP4's strategy in developing RNA-targeting therapeutics for various genetic diseases. The conference will be accessible through a webcast, which will also be archived for future viewing. CAMP4's proprietary RAP Platform aims to enhance gene expression through targeting regulatory RNAs.
Read more →CAMPCAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMP4 Therapeutics Corporation announced a successful pricing of its underwritten offering of 5 million shares of common stock at $6.00 per share, expected to generate $30 million in gross proceeds. The funds are intended to bolster the development of the company's regulatory RNA-targeting therapeutics aimed at treating genetic diseases. The offering is supported by participation from both new and existing investors and is set to close by December 19, 2025. Leerink Partners is the sole underwriter for this offering.
Read more →CAMPCAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries Collaboration to leverage CAMP4's RAP Platform to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegene
CAMP4 Therapeutics has entered a strategic collaboration with GlaxoSmithKline (GSK) to develop antisense oligonucleotides (ASOs) targeting neurodegenerative and kidney diseases. Under the agreement, CAMP4 will receive an upfront payment of $17.5 million, along with possibilities for milestone-based payments and royalties. The collaboration aims to leverage CAMP4's RAP Platform to discover and develop ASO drug candidates. GSK will oversee the further development and commercialization efforts, combining their expertise with CAMP4's RNA-targeting technology.
Read more →CAMPCAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics reported its third quarter 2025 financial results, highlighting a strengthened balance sheet due to a $100 million private placement. The company initiated GLP toxicology studies for CMP-002, aiming for a Phase 1/2 clinical trial in 2026. Additionally, favorable safety results were noted in the CMP-001 Phase 1 trial, although the net loss increased compared to the previous year.
Read more →CAMPCAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
CAMP4 Therapeutics has announced the initiation of GLP toxicology studies for its lead candidate, CMP-SYNGAP-01, which aims to treat SYNGAP1-related disorders. This development supports their plans for a clinical trial application, potentially leading to a Phase 1/2 trial in 2026. The candidate has shown promising preclinical results, restoring SYNGAP1 protein levels in relevant models.
Read more →CAMPCAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
CAMP4 Therapeutics has announced an oversubscribed private placement, raising up to $100 million to fund its SYNGAP1 program. The financing includes an initial $50 million and potential additional proceeds tied to regulatory milestones. Leadership changes have also occurred, with Doug Williams appointed as Board Chair and Dan Tardiff as Chief Scientific Officer. The Phase 1/2 clinical trial is expected to start in the second half of 2026.
Read more →CAMPCAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics Corporation reported its financial results for Q2 2025 and highlighted significant corporate updates. They presented promising translational data from their SYNGAP1-related disorders program at a key conference and are initiating GLP toxicology studies for CMP-SYNGAP-01 in Q3 2025. Additionally, they anticipate releasing data from multiple cohorts of their CMP-CPS-001 trial in Q4 and remain confident in advancing their therapies despite ongoing financial losses.
Read more →CAMPCAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting
CAMP4 Therapeutics presented promising data on its SYNGAP1-related disorders and Urea Cycle Disorders programs at the 28th American Society of Gene and Cell Therapy Annual Meeting. The CMP-SYNGAP-01 treatment demonstrated increased SYNGAP1 protein levels in non-human primates, while the Phase 1 trial of CMP-CPS-001 showed favorable safety and pharmacokinetics. The company aims to address significant unmet needs in genetic diseases.
Read more →CAMPDocument CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle
CAMP4 Therapeutics recently presented data showcasing the effectiveness of CMP-SYNGAP-01 in increasing SYNGAP1 protein levels in relevant brain regions of non-human primates at the 28th American Society of Gene and Cell Therapy Annual Meeting. The company also provided favorable safety and pharmacokinetic results for its Phase 1 trial of CMP-CPS-001 in healthy volunteers, indicating promising therapeutic potential. While the data presents a hopeful outlook for treating SYNGAP1-related disorders and Urea Cycle Disorders, CAMP4 acknowledges various risks associated with ongoing clinical development and financing.
Read more →CAMPDocument CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights - Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD)
CAMP4 Therapeutics has reported its financial results for the first quarter of 2025, highlighting progress in its clinical trials, including the completion of dosing in multiple cohorts for CMP-CPS-001 targeting Urea Cycle Disorders. The company has submitted a Clinical Trial Application in Europe for a Phase 1b trial and anticipates receiving milestone payments from its agreement with Fulcrum Therapeutics. Positive data from preclinical studies on its SYNGAP1-related disorders program were also discussed. Despite these advancements, CAMP4 continues to experience significant net losses and has rising R&D costs.
Read more →CAMPCAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
CAMP4 Therapeutics reported its first-quarter financial results for 2025, highlighting clinical advances and ongoing trials. The company is conducting a Phase 1 clinical trial of CMP-CPS-001 for Urea Cycle Disorders, and it has submitted a CTA for a Phase 1b trial in Europe. Additionally, CAMP4 anticipates receiving a milestone payment from Fulcrum Therapeutics, validating its product development. Despite these advancements, the company continues to incur significant losses and increased operating costs.
Read more →CAMPCAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
CAMP4 Therapeutics will present new preclinical data on their regulatory RNA-targeting therapies at the 28th Annual Meeting of the American Society of Gene and Cell Therapy. The presentations will include interim safety data from their Phase 1 trial of CMP-CPS-001, aimed at treating Urea Cycle Disorders and SYNGAP1-Related Disorders. These findings highlight the potential of their innovative approach to gene expression modulation.
Read more →CAMPCAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
CAMP4 Therapeutics reported its full-year 2024 financial results and provided a corporate update, highlighting ongoing Phase 1 trials for CMP-CPS-001 in Urea Cycle Disorders (UCDs) and the initiation of a Phase 1b trial in female OTC heterozygotes. The company also announced the nomination of CMP-SYNGAP-01 for SYNGAP1-related disorders. Despite a net loss increase, CAMP4 remains optimistic about its clinical advancements and financial position.
Read more →CAMPDocument CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update - Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascendin
CAMP4 Therapeutics reported its full-year financial results for 2024, highlighting the ongoing Phase 1 clinical trial of CMP-CPS-001 for Urea Cycle Disorders. The company plans to expand its trials and reported promising safety results from initial studies. Financial results include a net loss of $51.8 million, indicating ongoing investment in research and development. Additionally, CAMP4 announced the nomination of CMP-SYNGAP-01 for treating SYNGAP1-related disorders, reflecting its commitment to addressing critical gaps in genetic disease care.
Read more →CAMPCAMP4 Appoints Multiple Industry Veterans to its Board of Directors
CAMP4 Therapeutics has appointed Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to its Board of Directors. Their extensive experience in R&D and clinical development is expected to enhance CAMP4's strategic direction, particularly in advancing therapies for urea cycle disorders and SYNGAP1-related disorders. The company aims to develop RNA-targeting medicines to address genetic diseases.
Read more →CAMPCAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMP4 Therapeutics Corporation will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. CEO Josh Mandel-Brehm is scheduled to speak at 3:45 p.m. PST. The presentation aims to inform stakeholders about the company's progress in developing antisense oligonucleotide therapies. The event will be available via live webcast, with a replay accessible for 30 days afterward.
Read more →CAMPPioneering a new class of RNA medicines to increase targeted gene expression Corporate Overview January 2025 Forward - Looking Statements This presentation contains forward - looking statements that are based on the beli
CAMP4 is at the forefront of developing novel RNA medicines designed to enhance targeted gene expression. The company utilizes its proprietary RAP Platform to discover gene regulatory RNA and develop therapies for metabolic and CNS genetic diseases. Upcoming clinical data from their Phase 1 study is expected in the second half of 2025. Despite promising advancements, CAMP4 faces several uncertainties regarding the safety, efficacy, and regulatory approvals of its product candidates.
Read more →CAMPCAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones
CAMP4 Therapeutics Corporation provided several corporate updates and outlined key milestones for 2025, including favorable safety results for their lead program, CMP-CPS-001, which targets urea cycle disorders. The company, which successfully completed an IPO, has raised substantial funds to support its pipeline development. Upcoming milestones include data from multiple ascending dose clinical trials and the initiation of new discovery programs aimed at treating Parkinson's disease. CAMP4 was also recently added to the Russell 2000 Index, further enhancing its market presence.
Read more →CAMPCAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
CAMP4 Therapeutics Corporation has announced the appointments of John Maraganore and Rachel Meyers as strategic advisors. Maraganore, who led Alnylam's RNA interference programs, and Meyers, a seasoned expert in RNA-based medicines, are expected to contribute their substantial experience to CAMP4's efforts in advancing gene expression therapies. This move underscores CAMP4's commitment to developing therapeutics aimed at treating a range of genetic diseases, positioning the company for a potentially impactful future in the biopharmaceutical landscape.
Read more →CAMPCAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMP4 Therapeutics Corporation has announced its participation in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 3rd to 5th, 2024. Management will present on December 5th and will be available for one-on-one meetings with institutional contacts. The event is significant for the company as it continues to develop regRNA-targeting therapeutics aimed at addressing genetic diseases. A live webcast of the presentation will be accessible through the company's investor relations website.
Read more →CAMPCAMP4 Reports Third Quarter 2024 Financial Results - Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M - Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 complet
CAMP4 Therapeutics Corporation has reported its third quarter 2024 financial results, highlighting a successful IPO that raised $82.1 million. The company is engaged in the development of CMP-CPS-001, which completed its Single Ascending Dose phase and is anticipated to yield safety data in Q1 2025. Additionally, CAMP4 has established a research collaboration with BioMarin worth over $370 million. Despite reporting a net loss of $13.5 million for the quarter, the firm is optimistic about its financial positioning and upcoming clinical milestones.
Read more →CAMPCAMP4 Announces Pricing of Initial Public Offering
CAMP4 Therapeutics Corporation has announced the pricing of its initial public offering (IPO) of 6,820,000 shares at $11.00 per share, aiming to raise approximately $75.0 million. The shares are set to begin trading on the Nasdaq under the ticker symbol 'CAMP' on October 11, 2024, with the offering expected to close on October 15, 2024, pending customary closing conditions. This marks a significant milestone for CAMP4 as it seeks to advance its pipeline of RNA-targeting therapeutics for genetic diseases. The company has also granted underwriters an option to purchase additional shares within a set period.
Read more →CAMPCAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions
CAMP4 Therapeutics has entered a strategic research collaboration with BioMarin Pharmaceutical to advance RNA-targeting therapies for rare genetic diseases. This partnership aims to leverage BioMarin's drug development expertise alongside CAMP4's RAP Platform, which identifies regulatory RNA sequences controlling gene expression. As part of the agreement, BioMarin will select two targets from CAMP4's discoveries for clinical development. The collaboration could enhance the development of novel treatments and benefit patients with genetic conditions.
Read more →CAMPCAMP4 Therapeutics Secures Orphan Drug Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
CAMP4 Therapeutics has received Orphan Drug Designation from the FDA for CMP-CPS-001, aimed at treating urea cycle disorders (UCDs). This designation is crucial as there are no current disease-modifying therapies for these conditions. The investigational drug, which is undergoing a Phase 1 clinical trial, may significantly improve health outcomes by increasing the levels of a key enzyme involved in ammonia conversion. CAMP4's efforts could pave the way for innovative treatments in this critical area of need.
Read more →CAMPCAMP4 Therapeutics Secures Rare Pediatric Disease Designation for CMP-CPS-001 for the Treatment of Urea Cycle Disorders
CAMP4 Therapeutics announced that its lead drug candidate CMP-CPS-001 has been granted Rare Pediatric Disease Designation by the FDA for the treatment of urea cycle disorders. Currently, there are no disease-modifying treatments available for these severe metabolic disorders, which can lead to serious health complications. CMP-CPS-001 aims to upregulate gene expression related to a key enzyme in the urea cycle, potentially providing a novel therapeutic solution. A Phase 1 trial is underway to evaluate the candidate's safety and pharmacokinetics.
Read more →CAMPCAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
CAMP4 Therapeutics Corp. has successfully dosed the first participant in its Phase 1 clinical trial of CMP-CPS-001, aimed at treating urea cycle disorders (UCDs). This milestone marks the company's first investigational drug in clinical development and showcases their innovative mRNA-amplifying therapeutic approach. UCDs, severe metabolic diseases, currently lack approved disease-modifying treatments, highlighting the potential impact of CMP-CPS-001. The trial, which is randomized and placebo-controlled, will enroll 96 participants to assess the safety and efficacy of this promising candidate.
Read more →Competitive Position
How CAMP ranks across every disease it competes inCompetitive Position is a premium feature
See how CAMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial